Updated data from IMbrave050: Adjuvant atezolizumab plus bevacizumab for high-risk hepatocellular carcinoma
Adam C. Yopp, M. C. Chen, Ann-Lii Cheng, Ahmed Kaseb, Masatoshi Kudo, Han Chu Lee, Edward Cha, Stephen P. Hack, Qinshu Lian, Jessica Spahn, Chun Wu, Shukui Qin, Pierce Kah-Hoe Chow
Topics & Concepts
AtezolizumabBevacizumabMedicineAdjuvantOncologyInternal medicineInterim analysisHepatocellular carcinomaPerioperativeAdjuvant therapyAdjuvant chemotherapyImmunotherapyInterimSubgroup analysisOverall survivalClinical trialSurgeryCarcinomaSurvival rateProspective cohort studyHepatocellular Carcinoma Treatment and PrognosisCholangiocarcinoma and Gallbladder Cancer StudiesLiver physiology and pathology